antiviral innate immunity - Biweekly newsletter of the International Cytokine & Interferon Society

From ICIS-Pfizer Junior Investigator to McGill University Assistant Professor – Dr. GuanQun ‘Leo’ Liu

January 16, 2024

Dr. GuanQun ‘Leo’ Liu, the recipient of the Cytokines 2021 Pfizer Junior Investigator Award, is joining the Department of Microbiology and Immunology at McGill University as an Assistant Professor in March 2024… [READ MORE]

Graphical abstract and citation of recent article from lab of Dr. Edward Chuong

“Regulation of human interferon signaling by transposon exonization” published in Cell

February 3, 2025

The following interview was conducted by Signals+ Editor Maialen Sebastian-delaCruz, Ph.D. Connect with her on LinkedIn. A recent study by Pasquesi et al from the Chuong lab published in Cell, “Regulation of human interferon signaling by transposon exonization” showed that transposable element exonization can yield functional protein isoforms as seen for [READ MORE]

Elias A. Said, Ph.D., Associate Professor, Sultan Qaboos University, Muscat, Oman

Member Highlight: Meet Elias Said

February 3, 2025

The following interview was conducted by Signals+ Editor Maialen Sebastian-delaCruz, Ph.D. Connect with her on LinkedIn. I am a researcher in the Immunology field, specifically innate immunity and cytokines. Also, an Associate Editor for scientific journals. My research has led to significant achievements, such as identifying the role of PD-1 in [READ MORE]

Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

February 3, 2025

ClinicalTrials.gov ID NCT05600920 Sponsor National Institute of Allergy and Infectious Diseases (NIAID) Information provided by National Institutes of Health Clinical Center (CC) (National Institute of Allergy and Infectious Diseases (NIAID)) Study Overview Brief Summary Background: Idiopathic CD4 lymphopenia (ICL) is a syndrome characterized by low levels of certain immune cells [READ MORE]

Serum IL 26 as a Marker of Disease Activity in SLE

February 3, 2025

ClinicalTrials.gov ID NCT05161988 Sponsor: Assiut University Information provided by Fatma alzahraa Mustafa Abdelbary Thabet, Assiut University (Responsible Party) Study Overview Brief Summary Assessment of serum Interleukin 26 level in SLE patients and compare it with healthy controls. Association of serum interleukin 26 with SLE activity and severity. Detailed Description Systemic [READ MORE]

Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion

February 3, 2025

ClinicalTrials.gov ID NCT05693727 Sponsor: Assiut University Information provided by Mona Adel, Assiut University (Responsible Party) Study Overview Brief Summary To evaluate the ability of cancer ratio and pleural fluid markers to discriminate between malignant and non malignant effusion Detailed Description Pleural effusion is a common clinical entity affecting approximately 1.5 [READ MORE]

Share this: